PUBLISHED DATE : Aug 2023 | Pages : 202
Fill out your details & get your free sample
The South Africa Biopharmaceuticals Market Size, Share, & Trends Analysis Report by
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2023–2028.
202 Pages
28 Tables
76 Charts
1 Regions
1 Countries
16 Companies
2 Market Segment
| Report Attribute | Details |
|---|---|
| Market Size (2028) | USD 2.21 Billion |
| Market Size (2022) | USD 1.10 Billion |
| CAGR (2022-2028) | 12.30% |
| Base Year | 2022 |
| Forecast Year | 2023-2028 |
| Market Segments | Product and Therapy Area |
| Geographic Analysis | South Africa |
| KEY VENDORS | AbbVie, F. Hoffmann-la Roche, GSK, Johnson & Johnson, Merck & Co., Novartis, Novo Nordisk, Pfizer, and Sanofi |
The South Africa biopharmaceuticals market was valued at USD 1.10 billion in 2022 and is expected to reach USD 2.21 billion by 2028, growing at a CAGR of 12.30%. The market has been experiencing significant growth and evolution in recent years. The country's commitment to advancing healthcare infrastructure, research, and development, combined with supportive regulatory policies, has contributed to the increased availability and adoption of biologics in the healthcare system.
Biopharmaceuticals, known as biologics, represent a class of advanced medical therapies derived from living organisms or their components. These innovative drugs have transformed the healthcare landscape, offering targeted and personalized treatments for various chronic and complex diseases. The South Africa biopharmaceuticals market has gained increasing attention and is becoming an essential component of modern healthcare, aiming to address unmet medical needs and improve patient outcomes.
As the region grapples with the rising burden of chronic diseases, infectious diseases, and an aging population, the South Africa biopharmaceuticals market offers new hope for more effective treatments, disease management, and improved quality of life. Understanding the role of biologics in the South African healthcare system is essential to inform policymakers, healthcare providers, and patients as the country continues to explore innovative solutions for better healthcare outcomes and enhanced patient care.
Promising Signs for Local Biopharmaceutical Production in South Africa
The promising signs for local biopharmaceutical production in South Africa reflect a growing interest in developing a robust and self-sufficient pharmaceutical industry. With strong government support, research advancements, collaborative partnerships, and a focus on addressing healthcare demands, the country is poised to make significant strides in biopharmaceuticals. By fostering local production, the South Africa biopharmaceuticals market can improve access to essential medicines, drive healthcare innovation, and contribute to economic development, ultimately benefiting the healthcare sector and the well-being of its population.
Growing Pharmaceutical Industry & Investment Opportunities
The growing South Africa biopharmaceuticals market presents ample investment opportunities for companies and investors. The country's expanding market size, disease burden, government support, local manufacturing focus, robust regulatory environment, and potential for regional market access contribute to its attractiveness as a pharmaceutical investment destination. As the healthcare landscape continues to evolve, companies investing in research, development, and manufacturing capabilities are well-positioned to capitalize on the country's burgeoning pharmaceutical market and improve healthcare outcomes for the South African population and beyond.
Growing Access to CGTs in South Africa
The growing access to cell and gene therapies in South Africa presents a transformative opportunity to revolutionize healthcare and improve patient outcomes. With the potential to address genetic and rare diseases, enhance cancer care, and offer personalized medicine, these therapies are poised to impact healthcare delivery profoundly. As the South Africa biopharmaceuticals market embraces these innovations and establishes supportive policies and infrastructure, the region can position itself at the forefront of biomedical research and become a hub for cutting-edge therapies, unlocking new possibilities for patients and healthcare providers.
Increasing Prevalence of Chronic Diseases & Growing Aging Population
The increasing prevalence of chronic diseases and the growing aging population in South Africa are compelling factors that necessitate a proactive and comprehensive approach to healthcare. Addressing these challenges requires strategic planning, increased investment in healthcare infrastructure, preventive health initiatives, and equitable access to healthcare services. By focusing on these areas, South Africa can improve health outcomes, enhance the quality of life for its citizens, and build a more resilient and sustainable healthcare system to meet future needs.
Increasing Focus on Precision Medicine
The increasing focus on precision medicine in South Africa marks a transformative shift in healthcare, offering the potential to revolutionize patient care and disease management. By leveraging genomic data, health informatics, and targeted therapies, precision medicine aims to deliver more effective, personalized, and patient-centric healthcare solutions. As the region continues to advance its precision medicine capabilities, integrating genomic insights into clinical practice holds the promise of improving health outcomes, reducing healthcare costs, and enhancing the quality of life for the population.
INSIGHTS BY PRODUCT
The South Africa biopharmaceuticals market by product segments as vaccines, monoclonal antibodies, recombinant proteins & hormones, and tissue, cell & gene therapies. The vaccines segment accounted for the largest segmental share. Vaccines are pivotal in public health, preventing and controlling infectious diseases that threaten communities worldwide. In South Africa, vaccines are a cornerstone of the biopharmaceuticals market, providing essential protection against various infectious diseases and contributing to the nation's efforts to improve public health and healthcare outcomes. Government initiatives and partnerships with international organizations have been instrumental in driving vaccine development and distribution in South Africa. The country’s government, WHO, and other global health entities have implemented immunization programs targeting various age groups and high-risk populations.
INSIGHTS BY THERAPY AREA
The infectious diseases by therapy area segment accounted for the largest South Africa biopharmaceuticals market share. Infectious diseases have long been a significant public health concern in South Africa, posing challenges to the healthcare system and population. The country's biopharmaceutical market is crucial in addressing these challenges by providing innovative and effective treatments and preventive measures against infectious diseases. The biopharmaceuticals market in the region has played a pivotal role in addressing infectious diseases through developing and distributing vaccines, antiviral drugs, antibiotics, and other therapeutics. Antiretroviral therapy (ART) has been a game-changer in managing HIV/AIDS, improving HIV-positive individuals' quality of life and life expectancy.
The South Africa biopharmaceuticals market is a dynamic and rapidly growing sector, driven by increasing healthcare needs, a rising burden of chronic diseases, and advancements in medical research and biotechnology. The industry is characterized by intense competition among pharmaceutical companies vying for a share in this lucrative and critical industry.
Companies operating in the market diversify their product portfolios to cater to a broad range of medical conditions. A diverse portfolio allows companies to address therapeutic areas and leverage growth opportunities. Further, collaboration, expansion, and new product launches are essential strategies that companies in the South Africa biopharmaceuticals market use to strengthen their presence, accelerate growth, and meet the evolving healthcare needs of the population. Several companies have embraced these approaches to foster innovation and enhance their industry position. For instance, Johnson & Johnson partnered with leading South African research institutions and academic centers to collaborate on research projects on infectious diseases, HIV/AIDS, and tuberculosis. These collaborations aim to advance scientific knowledge, develop new treatments, and address healthcare challenges specific to the region.
Frequently Asked Questions
How big is the South African biopharmaceuticals market?
The South Africa biopharmaceuticals market size was valued at USD 1.10 billion in 2022 and is expected to reach USD 2.21 billion by 2028.
What is the South Africa biopharmaceuticals market's projected growth rate?
The South Africa biopharmaceuticals market is projected to grow at a CAGR of 12.30% during the forecast period.
Who are the key players in the South Africa biopharmaceuticals market?
AbbVie, F. Hoffmann-la Roche, GSK, Johnson & Johnson, Merck & Co., Novartis, Novo Nordisk, Pfizer, and Sanofi are the key players in the South African biopharmaceuticals market.
What are the rising trends in the South African biopharmaceuticals market?
The rising trends in the South African biopharmaceuticals industry are promising signs for local biopharmaceutical production in the region, increasing adoption of biosimilars, growing pharmaceutical industry & investment opportunities, and growing access to CGT in South Africa.
Which therapy area holds the most significant South African biopharmaceuticals market share?
The infectious diseases therapy area dominated the South African biopharmaceuticals market, accounting for over 42% in 2022.
The South Africa biopharmaceuticals market size is expected to grow at a CAGR of approximately 12.30% from 2022 to 2028.
The following factors are likely to contribute to the growth of the South Africa biopharmaceuticals market during the forecast period:
Base Year: 2022
Forecast Year: 2023-2028
The report considers the present scenario of the South Africa biopharmaceuticals market and its market dynamics for 2023−2028. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the industry. It also profiles and analyzes leading companies and several other prominent companies operating in the industry.
Key Company Profiles
Other Prominent Vendors
Segmentation by Product
Segmentation by Therapy Area
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY PRODUCT
4.3.2 MARKET SEGMENTATION BY THERAPY AREA
4.3.3 MARKET SEGMENTATION BY GEOGRAPHY
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 MARKET AT A GLANCE
7 PREMIUM INSIGHTS
7.1 OVERVIEW
7.1.1 PRODUCT SEGMENTATION INSIGHTS
7.1.2 THERAPY AREA SEGMENTATION INSIGHTS
8 INTRODUCTION
8.1 BIOPHARMACEUTICALS: OVERVIEW
8.1.1 GLOBAL BIOPHARMACEUTICALS MARKET SCENARIO
8.1.2 SOUTH AFRICA BIOPHARMACEUTICALS MARKET SCENARIO
8.2 BIOPHARMA MANUFACTURING
8.2.1 ADVANCES IN BIOPHARMA MANUFACTURING
8.2.2 IMPORTANCE OF SINGLE-USE BIOPROCESSING IN BIOLOGICS MANUFACTURING
8.3 REGULATORY SCENARIO OF BIOPHARMACEUTICALS IN SOUTH AFRICA
8.4 REIMBURSEMENT SCENARIO OF BIOPHARMACEUTICALS IN SOUTH AFRICA
8.5 SUPPLY CHAIN OF BIOPHARMACEUTICALS
8.6 COVID-19 IMPACT ANALYSIS
8.6.1 POSSIBLE IMPACT OF THE COVID-19 PANDEMIC ON THE BIOPHARMACEUTICALS MARKET
8.6.2 PRE-COVID & POST-COVID MARKET SCENARIO OF BIOPHARMACEUTICALS
9 MARKET OPPORTUNITIES & TRENDS
9.1 PROMISING SIGNS FOR LOCAL BIOPHARMACEUTICAL PRODUCTION IN SOUTH AFRICA
9.2 INCREASED ADOPTION OF BIOSIMILARS
9.3 GROWTH OF PHARMACEUTICAL INDUSTRY & INVESTMENT OPPORTUNITIES
9.4 INCREASED ACCESS TO CGT IN SOUTH AFRICA
10 MARKET GROWTH ENABLERS
10.1 PREVALENCE OF CHRONIC DISEASES & LARGE AGING POPULATION
10.1.1 TOP CHRONIC DISEASES IN SOUTH AFRICA
10.2 INCREASED FOCUS ON PRECISION MEDICINE
10.3 BIOLOGICS UPTAKE & POTENTIAL IN SOUTH AFRICA
11 MARKET RESTRAINTS
11.1 LACK OF MANUFACTURING CAPABILITIES
11.2 HIGH DEVELOPMENT COST OF BIOLOGICS
11.3 POOR PATIENT ACCEPTANCE & ACCESS TO BIOLOGICS
12 MARKET LANDSCAPE
12.1 MARKET OVERVIEW
12.2 MARKET SIZE & FORECAST
12.3 MARKET OPPORTUNITY
12.3.1 MARKET OPPORTUNITY BY PRODUCT
12.3.2 MARKET OPPORTUNITY BY THERAPY AREA
12.4 FIVE FORCES ANALYSIS
12.4.1 THREAT OF NEW ENTRANTS
12.4.2 BARGAINING POWER OF SUPPLIERS
12.4.3 BARGAINING POWER OF BUYERS
12.4.4 THREAT OF SUBSTITUTES
12.4.5 COMPETITIVE RIVALRY
13 PRODUCT
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 VACCINES
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.4 MONOCLONAL ANTIBODIES
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.5 RECOMBINANT PROTEINS & HORMONES
13.5.1 MARKET OVERVIEW
13.5.2 MARKET SIZE & FORECAST
13.6 TISSUE, CELL & GENE THERAPIES
13.6.1 MARKET OVERVIEW
13.6.2 MARKET SIZE & FORECAST
14 THERAPY AREA
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 INFECTIOUS DISEASES
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.4 DIABETES
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.5 ONCOLOGY
14.5.1 MARKET OVERVIEW
14.5.2 MARKET SIZE & FORECAST
14.6 INFLAMMATION & IMMUNOLOGY
14.6.1 MARKET OVERVIEW
14.6.2 MARKET SIZE & FORECAST
14.7 OTHER THERAPY ARAES
14.7.1 MARKET OVERVIEW
14.7.2 MARKET SIZE & FORECAST
15 COMPETITIVE LANDSCAPE
15.1 COMPETITION OVERVIEW
15.1.1 KEY HIGHLIGHTS OF SOUTH AFRICA BIOPHARMACEUTICALS MARKET
15.2 MARKET SHARE ANALYSIS
15.2.1 ABBVIE
15.2.2 F. HOFFMANN-LA ROCHE
15.2.3 GSK
15.2.4 JOHNSON & JOHNSON
15.2.5 MERCK & CO.
15.2.6 NOVARTIS
15.2.7 NOVO NORDISK
15.2.8 PFIZER
15.2.9 SANOFI
16 KEY COMPANY PROFILES
16.1 ABBVIE
16.1.1 BUSINESS OVERVIEW
16.1.2 PRODUCT OFFERINGS
16.1.3 KEY STRATEGIES
16.1.4 KEY STRENGTHS
16.1.5 KEY OPPORTUNITIES
16.2 F. HOFFMANN-LA ROCHE
16.2.1 BUSINESS OVERVIEW
16.2.2 PRODUCT OFFERINGS
16.2.3 KEY STRATEGIES
16.2.4 KEY STRENGTHS
16.2.5 KEY OPPORTUNITIES
16.3 GSK
16.3.1 BUSINESS OVERVIEW
16.3.2 PRODUCT OFFERINGS
16.3.3 KEY STRATEGIES
16.3.4 KEY STRENGTHS
16.3.5 KEY OPPORTUNITIES
16.4 JOHNSON & JOHNSON
16.4.1 BUSINESS OVERVIEW
16.4.2 PRODUCT OFFERINGS
16.4.3 KEY STRATEGIES
16.4.4 KEY STRENGTHS
16.4.5 KEY OPPORTUNITIES
16.5 MERCK & CO.
16.5.1 BUSINESS OVERVIEW
16.5.2 PRODUCT OFFERINGS
16.5.3 KEY STRATEGIES
16.5.4 KEY STRENGTHS
16.5.5 KEY OPPORTUNITIES
16.6 NOVARTIS
16.6.1 BUSINESS OVERVIEW
16.6.2 PRODUCT OFFERINGS
16.6.3 KEY STRATEGIES
16.6.4 KEY STRENGTHS
16.6.5 KEY OPPORTUNITIES
16.7 NOVO NORDISK
16.7.1 BUSINESS OVERVIEW
16.7.2 PRODUCT OFFERINGS
16.7.3 KEY STRATEGIES
16.7.4 KEY STRENGTHS
16.7.5 KEY OPPORTUNITIES
16.8 PFIZER
16.8.1 BUSINESS OVERVIEW
16.8.2 PRODUCT OFFERINGS
16.8.3 KEY STRATEGIES
16.8.4 KEY STRENGTHS
16.8.5 KEY OPPORTUNITIES
16.9 SANOFI
16.9.1 BUSINESS OVERVIEW
16.9.2 PRODUCT OFFERINGS
16.9.3 KEY STRATEGIES
16.9.4 KEY STRENGTHS
16.9.5 KEY OPPORTUNITIES
17 OTHER PROMINENT VENDORS
17.1 AMGEN
17.1.1 BUSINESS OVERVIEW
17.1.2 PRODUCT OFFERINGS
17.2 BIOCON
17.2.1 BUSINESS OVERVIEW
17.2.2 PRODUCT OFFERINGS
17.3 BIOGEN
17.3.1 BUSINESS OVERVIEW
17.3.2 PRODUCT OFFERINGS
17.4 CIPLA
17.4.1 BUSINESS OVERVIEW
17.4.2 PRODUCT OFFERINGS
17.5 ELI LILLY AND COMPANY
17.5.1 BUSINESS OVERVIEW
17.5.2 PRODUCT OFFERINGS
17.6 TEVA PHARMACEUTICAL INDUSTRIES
17.6.1 BUSINESS OVERVIEW
17.6.2 PRODUCT OFFERINGS
17.7 VIATRIS
17.7.1 BUSINESS OVERVIEW
17.7.2 PRODUCT OFFERINGS
18 REPORT SUMMARY
18.1 KEY TAKEAWAYS
18.2 STRATEGIC RECOMMENDATIONS
19 QUANTITATIVE SUMMARY
19.1 MARKET BY PRODUCT
19.2 MARKET BY THERAPY AREA
20 APPENDIX
20.1 ABBREVIATIONS
EXHIBIT 1 SEGMENTATION OF SOUTH AFRICA BIOPHARMACEUTICALS MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2022
EXHIBIT 3 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY PRODUCT: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 4 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY THERAPY AREA: MARKET SHARE 2022 & 2028 (%)
EXHIBIT 5 GLOBAL BIOPHARMACEUTICALS MARKET 2022–2028 ($ BILLION)
EXHIBIT 6 SUMMARY OF THE BIOLOGICAL MEDICINES EVALUATION AND RESEARCH UNIT (BMERU) REGULATORY REQUIREMENTS FOR BIOLOGIC & BIOSIMILAR COMPOUNDS IN SOUTH AFRICA
EXHIBIT 7 COMPARISON OF REQUIREMENTS FOR REGISTRATION OF A BIOSIMILAR & REFERENCE MEDICINAL PRODUCT
EXHIBIT 8 IMPACT OF PROMISING SIGNS FOR LOCAL BIOPHARMACEUTICAL PRODUCTION IN SOUTH AFRICA
EXHIBIT 9 IMPACT OF INCREASED ADOPTION OF BIOSIMILARS
EXHIBIT 10 IMPACT OF GROWTH OF PHARMACEUTICAL INDUSTRY & INVESTMENT OPPORTUNITIES
EXHIBIT 11 IMPACT OF INCREASED ACCESS TO CGT IN SOUTH AFRICA
EXHIBIT 12 IMPACT OF PREVALENCE OF CHRONIC DISEASES & LARGE AGING POPULATION
EXHIBIT 13 IMPACT OF INCREASED FOCUS ON PRECISION MEDICINE
EXHIBIT 14 IMPACT OF BIOLOGICS UPTAKE & POTENTIAL IN SOUTH AFRICA
EXHIBIT 15 IMPACT OF LACK OF MANUFACTURING CAPABILITIES
EXHIBIT 16 IMPACT OF HIGH DEVELOPMENT COST OF BIOLOGICS
EXHIBIT 17 IMPACT OF POOR PATIENT ACCEPTANCE & ACCESS TO BIOLOGICS
EXHIBIT 18 SOUTH AFRICA BIOPHARMACEUTICALS MARKET 2022–2028 ($ MILLION)
EXHIBIT 19 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY PRODUCT: MARKET OPPORTUNITY OVERVIEW
EXHIBIT 20 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY THERAPY AREA: MARKET OPPORTUNITY OVERVIEW
EXHIBIT 21 FIVE FORCES ANALYSIS 2022
EXHIBIT 22 INCREMENTAL GROWTH BY PRODUCT 2022 & 2028
EXHIBIT 23 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY PRODUCT 2022–2028: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 24 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY PRODUCT 2022–2028: ABSOLUTE GROWTH (%)
EXHIBIT 25 SOUTH AFRICA VACCINES MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 26 SOUTH AFRICA VACCINES MARKET 2022–2028 ($ MILLION)
EXHIBIT 27 SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 28 SOUTH AFRICA MONOCLONAL ANTIBODIES MARKET 2022–2028 ($ MILLION)
EXHIBIT 29 SOUTH AFRICA RECOMBINANT PROTEINS & HORMONES MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 30 SOUTH AFRICA RECOMBINANT PROTEINS & HORMONES MARKET 2022–2028 ($ MILLION)
EXHIBIT 31 SOUTH AFRICA TISSUE, CELL & GENE THERAPIES MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 32 SOUTH AFRICA TISSUE, CELL & GENE THERAPIES MARKET 2022–2028 ($ MILLION)
EXHIBIT 33 INCREMENTAL GROWTH BY THERAPY AREA 2022 & 2028
EXHIBIT 34 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY THERAPY AREA 2022–2028: INCREMENTAL GROWTH ($ MILLION)
EXHIBIT 35 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY THERAPY AREA 2022–2028: ABSOLUTE GROWTH (%)
EXHIBIT 36 SOUTH AFRICA INFECTIOUS DISEASES BIOPHARMACEUTICALS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 37 SOUTH AFRICA INFECTIOUS DISEASES BIOPHARMACEUTICALS MARKET 2022–2028 ($ MILLION)
EXHIBIT 38 SOUTH AFRICA DIABETES BIOPHARMACEUTICALS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 39 SOUTH AFRICA DIABETES BIOPHARMACEUTICALS MARKET 2022–2028 ($ MILLION)
EXHIBIT 40 SOUTH AFRICA ONCOLOGY BIOPHARMACEUTICALS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 41 SOUTH AFRICA ONCOLOGY BIOPHARMACEUTICALS MARKET 2022–2028 ($ MILLION)
EXHIBIT 42 SOUTH AFRICA INFLAMMATION & IMMUNOLOGY BIOPHARMACEUTICALS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 43 SOUTH AFRICA INFLAMMATION & IMMUNOLOGY BIOPHARMACEUTICALS MARKET 2022–2028 ($ MILLION)
EXHIBIT 44 SOUTH AFRICA OTHER THERAPY AREAS BIOPHARMACEUTICALS MARKET 2022–2028: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 45 SOUTH AFRICA OTHER THERAPY AREAS BIOPHARMACEUTICALS MARKET 2022–2028 ($ MILLION)
EXHIBIT 46 VENDORS THAT OFFER COMMERCIAL BIOPHARMACEUTICALS: MARKET DOMINANCE ANALYSIS
EXHIBIT 47 VENDORS THAT OFFER COMMERCIAL BIOPHARMACEUTICALS: CAPABILITIES & EXPERTISE ASSESSMENT
EXHIBIT 48 ABBVIE: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 49 ABBVIE: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 50 F. HOFFMANN-LA ROCHE: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 51 F. HOFFMANN-LA ROCHE: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 52 F. HOFFMANN-LA ROCHE: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 53 GSK: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 54 GSK: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 55 JOHNSON & JOHNSON: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 56 JOHNSON & JOHNSON: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 57 JOHNSON & JOHNSON: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 58 JOHNSON & JOHNSON: REVENUE BY GEOGRAPHIC REGION 2022 ($ BILLION)
EXHIBIT 59 MERCK & CO.: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 60 MERCK & CO.: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 61 MERCK & CO.: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 62 MERCK & CO.: REVENUE BY GEOGRAPHIC REGION 2022 ($ BILLION)
EXHIBIT 63 NOVARTIS: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 64 NOVARTIS: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 65 NOVARTIS: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 66 NOVARTIS: REVENUE BY GEOGRAPHY 2022 ($ BILLION)
EXHIBIT 67 NOVO NORDISK: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 68 NOVO NORDISK: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 69 PFIZER: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 70 PFIZER: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 71 PFIZER: REVENUE BY BUSINESS SEGMENT 2021 ($ BILLION)
EXHIBIT 72 PFIZER: REVENUE BY GEOGRAPHIC REGION 2021 ($ BILLION)
EXHIBIT 73 SANOFI: TOTAL REVENUE 2020–2022 ($ BILLION)
EXHIBIT 74 SANOFI: R&D EXPENDITURE 2020–2022 ($ BILLION)
EXHIBIT 75 SANOFI: REVENUE BY BUSINESS SEGMENT 2022 ($ BILLION)
EXHIBIT 76 SANOFI: REVENUE BY GEOGRAPHIC REGION 2022 ($ BILLION)
LIST OF TABLES
TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION 2016–2022
TABLE 3 SOUTH AFRICA: OVERVIEW
TABLE 4 SUMMARY OF CROSS-COUNTRY ANALYSIS
TABLE 5 EFFECTS OF BIOSIMILAR LAUNCH ON ORIGINATOR STANDARD UNIT PRICE IN SOUTH AFRICA USING AVERAGE PRICE PER MOLECULE
TABLE 6 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY PRODUCT: MARKET SIZE 2022 & 2028 ($ MILLION)
TABLE 7 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY THERAPY AREA: MARKET SIZE 2022 & 2028 ($ MILLION)
TABLE 8 MABS APPROVED IN SOUTH AFRICA
TABLE 9 ABBVIE: MAJOR PRODUCT OFFERINGS
TABLE 10 F. HOFFMANN-LA ROCHE: MAJOR PRODUCT OFFERINGS
TABLE 11 GSK: MAJOR PRODUCT OFFERINGS
TABLE 12 JOHNSON & JOHNSON: MAJOR PRODUCT OFFERINGS
TABLE 13 MERCK & CO.: MAJOR PRODUCT OFFERINGS
TABLE 14 NOVARTIS: MAJOR PRODUCT OFFERINGS
TABLE 15 NOVO NORDISK: MAJOR PRODUCT OFFERINGS
TABLE 16 PFIZER: MAJOR PRODUCT OFFERINGS
TABLE 17 SANOFI: MAJOR PRODUCT OFFERINGS
TABLE 18 AMGEN: MAJOR PRODUCT OFFERINGS
TABLE 19 BIOCON: MAJOR PRODUCT OFFERINGS
TABLE 20 BIOGEN: MAJOR PRODUCT OFFERINGS
TABLE 21 CIPLA: MAJOR PRODUCT OFFERINGS
TABLE 22 ELI LILLY AND COMPANY: MAJOR PRODUCT OFFERINGS
TABLE 23 TEVA PHARMACEUTICAL INDUSTRIES: MAJOR PRODUCT OFFERINGS
TABLE 24 VIATRIS: MAJOR PRODUCT OFFERINGS
TABLE 25 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY PRODUCT 2022–2028 ($ BILLION)
TABLE 26 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY PRODUCT 2022–2028 (%)
TABLE 27 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY THERAPY AREA 2022–2028 ($ BILLION)
TABLE 28 SOUTH AFRICA BIOPHARMACEUTICALS MARKET BY THERAPY AREA 2022–2028 (%)
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
